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Abstract
Background The G1 and G2 alleles of apolipoprotein L1 (APOL1) are common in the Black population and associated with 
increased risk of focal segmental glomerulosclerosis (FSGS). The molecular mechanisms linking APOL1 risk variants with 
FSGS are not clearly understood, and APOL1’s natural absence in laboratory animals makes studying its pathobiology 
challenging.
Methods In a cohort of 90 Black patients with either FSGS or minimal change disease (MCD) enrolled in the Nephrotic Syndrome 
Study Network (58% pediatric onset), we used kidney biopsy traits as an intermediate outcome to help illuminate tissue-based 
consequences of APOL1 risk variants and expression. We tested associations between APOL1 risk alleles or glomerular APOL1 
mRNA expression and 83 light- or electron-microscopy traits measuring structural and cellular kidney changes.
Results Under both recessive and dominant models in the FSGS patient subgroup (61%), APOL1 risk variants were significantly 
correlated (defined as FDR <0.1) with decreased global mesangial hypercellularity, decreased condensation of cytoskeleton, and 
increased tubular microcysts. No significant correlations were detected in MCD cohort. Independent of risk alleles, glomerular 
APOL1 expression in FSGS patients was not correlated with morphologic features.
Conclusions While APOL1-associated FSGS is associated with two risk alleles, both one and two risk alleles are associated with 
cellular/tissue changes in this study of FSGS patients. Our lack of discovery of a large group of tissue differences in FSGS and no 
significant difference in MCD may be due to the lack of power but also supports investigating whether machine learning methods 
may more sensitively detect APOL1-associated changes.
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Introduction
Harboring two copies of the G1 and G2 alleles in apolipopro-
tein L1 (APOL1) confers significantly greater risk for nephrot-
ic syndrome (NS) with focal segmental glomerular sclerosis
(FSGS) histology [1, 2]. These APOL1 risk variants are spe-
cific to people of recentWest African ancestry, are common in
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the African-American population, and are evenmore common
in African-Americans with FSGS [3]. From a pediatric per-
spective, 60–70% ofAfrican-American childrenwith NS have
a high risk (HR, two risk alleles) APOL1 genotype. Compared
to children with NS and a low risk (LR, one or two risk alleles)
genotype, those with a HR genotype have a 3–10× greater
likelihood of being born prematurely, present with an average
17 ml/min/1.73m2 lower eGFR, are 1/3 less likely to achieve
complete remission of proteinuria, and have a faster decline of
eGFR over time [4, 5].
Altogether, this suggests that APOL1-associated NS is a
distinct form of glomerular disease that, while most often pre-
senting clinically as nephrotic syndrome and histologically as
FSGS, behaves clinically in a more severe and intractable
manner than the non-APOL1 forms of this condition.
Furthermore, the majority of Black children with NSwill have
APOL1-associated disease, meaning that a better understand-
ing of why this disease occurs holds great potential in helping
a large proportion of our patients in this population.
Massive effort has been directed toward discovering the
pathobiology underlying the association between these com-
mon genetic variants and kidney disease in order to ultimately
devise more rational, targeted therapies against this disease.
Experiments have been done at the bench using in vitro sys-
tems and in laboratory organisms in whom APOL1 has been
artificially engineered into them [6–10]. In humans, APOL1
genotype data have been combined with histological, molec-
ular, and/or clinical data to perform association studies be-
tween genotype, mRNA and protein expression, tissue alter-
ations, and clinical phenotype [11–14].
From a kidney morphology perspective, APOL1 risk
alleles were initially discovered through their association
with the morphologic diagnosis of FSGS and hypertensive
stage 5 chronic kidney disease and were linked soon there-
after to HIV-associated nephropathy (HIVAN) [15]. The
continued pursuit of relationships between APOL1 risk al-
leles and gene expression to kidney tissue abnormalities
has revealed specific patterns of injury to the kidney, lead-
ing to potential biologic and mechanistic insights in a bio-
logically informative way that is impossible to detect when
solely associating genotype to clinical phenotype. In lupus,
the APOL1 high-risk genotype has also been linked to glo-
merular collapse [16]. In FSGS patients, it has been asso-
ciated with more segmental and global glomerulosclerosis,
interstitial fibrosis, and tubular atrophy [14]. Patients with
PLA2R-associated membranous nephropathy and a high-
risk APOL1 genotype had significantly increased glomer-
ular collapse, FSGS lesions, cystic tubular dilatation, and
acute tubular injury [17]. In one study of biopsied patients
with chronic kidney disease (CKD) without nephrotic syn-
drome, Black patients with two APOL1 risk alleles had less
obsolescent glomerulosclerosis, more solidified and
disappearing glomerulosclerosis, thyroidization-type tubu-
lar atrophy, and microcystic tubular dilation [18].
Here, we hypothesized that studying kidney biopsy tissue
of children and adults with NS as a function of their APOL1
risk alleles and glomerular expression levels would lead to the
discovery of a morphologic signature of APOL1-associated
NS. To do so, we studied a cohort of 90 Black patients who
underwent kidney biopsies for proteinuric kidney disease in
the Nephrotic Syndrome Study Network (NEPTUNE) [19]
and were found to have FSGS or minimal change disease
(MCD). We integrated APOL1 genotyping, glomerular
mRNA expression levels, and research biopsy tissue measure-
ments to test for associations between APOL1 genotype,
APOL1 gene expression, and 83 research-based glomerular,
tubulointerstitial, and vascular traits (“descriptors”) noted by
light and electron microscopy [20].
Methods
Study sample
NEPTUNE is an ongoing multicenter prospective observa-
tional cohort study of children and adults with proteinuria at
screening of > 0.5 g/day (> 1.5 g/day in the second study
phase), most of whom are undergoing a clinically-indicated
kidney biopsy [19]. Blood, urine, and tissue samples were
collected at the time of biopsy, along with demographic infor-
mation and clinical characteristics. Only patients with MCD,
FSGS, or membranous nephropathy (MN) are eligible to con-
tinue in the NEPTUNE observational study. Kidney biopsy
tissue was collected at enrolling centers and sent to the NIH
image coordinating center, where stained glass slides were
scanned into whole slide images (WSI), and together with
the digital electron microscopy (EM) images, these images
were uploaded in the NEPTUNE Digital Pathology
Repository (DPR) [21]. The inclusion criteria for participants
in this study were (1) self-identified as Black race or had
genotype-based African ancestry, (2) histologic diagnosis of
FSGS or MCD, (3) APOL1 genotyping acquired, and (4) bi-
opsy obtained with research morphology scoring. Patients
with secondary causes of FSGS (e.g., HIV infection) were
not included in this study. Those individuals meeting inclu-
sion criteria who also had glomerular mRNA transcriptomic
data were included in the gene expression study described
below.
Morphology descriptor outcome variables
As previously published, pathologists within the NEPTUNE
consortium developed the NEPTUNE Digital Pathology
Scoring System which collects quantitative data on structural
changes observed in digital WSI and EM images of kidney
biopsy tissue. This system entails scoring 51 individual glo-
merular descriptors (which are subsequently used to calculate
the percentage of glomeruli in the biopsy with each feature),
11 tubulointerstitial and vascular descriptors relating to the
presence and amount of tubulointerstitial and vascular dam-
age, and 21 EM descriptors describing the presence and quan-
tity of abnormal ultrastructural features. These 83 descriptors
were used as dependent variables in the current study.
Pathologists also identified individual glomerular descrip-
tors that shared morphologic similarities, and these individual
descriptors were combined into 21 “grouped” glomerular de-
scriptors. We calculated the percentage of glomeruli in the
biopsy with any of the features in the group and also used
these grouped descriptors as dependent variables.
A list of the 83 descriptors and the 21 grouped glomerular
descriptors and their definitions are published and available in
tabular format [20].
Independent variables
The primary exposures of interest were APOL1 risk genotype
and glomerular APOL1 gene expression. The number of
APOL1 risk alleles for each participant was determined by
either whole genome sequencing (WGS), Sanger sequencing,
or both. To measure glomerular APOL1 gene expression, all
glomeruli were manually microdissected from biopsy tissue,
and RNA was extracted and sequenced (RNA-seq). RNA-seq
data were normalized and transformed to log-2 counts per
million (log2CPM) with the limma transformation.
Other demographic data used in the current study included
age at biopsy, sex, and Hispanic ethnicity. Clinical character-
istics included self/family-reported premature birth, glomeru-
lar disease diagnosis, estimated glomerular filtration rate
(eGFR) at kidney biopsy, and urine protein creatinine ratio
(UPCR) at biopsy. eGFR was estimated using the CKiD-
Schwartz equation for children, CKD-Epi equation for adults
over 26 years old, and an average of the two equations for
adults between 18–26 years old [22]. If available, serum cre-
atinine and UPCR were measured by a central laboratory
using collected biosamples; otherwise, local laboratory values
were used.
Statistical analysis
Demographic and clinical characteristics of participants in the
study sample were described using median and interquartile
range (IQR) for continuous variables and frequencies for cat-
egorical variables. We tested for differences in these charac-
teristics across number of APOL1 risk alleles using the
Kruskal–Wallis rank sum test for continuous variables,
Pearson’s chi-squared test for categorical variables with at
least five participants in each group, and Fisher’s exact test
for categorical variables with less than five participants in at
least one group. To test the hypothesis that a larger number of
APOL1 risk alleles were associated with higher glomerular
gene expression, we used Spearman’s correlation coefficient
and test.
We assessed associations between APOL1 risk genotypes
and each of 83 morphology descriptors using Spearman’s cor-
relation coefficient and test, under additive (comparing pa-
tients with 0 vs. 1 vs. 2 risk alleles) and recessive (comparing
patients who are LR (0 or 1 risk alleles) vs. patients who are
HR (2 risk alleles)) genetic models. Pathologists also com-
bined related individual glomerular descriptors into grouped
descriptors, and we repeated the process above using grouped
descriptors as our outcomes of interest. Spearman’s correla-
tion coefficient test with FDR correction was used to assess
associations between the level of glomerular APOL1 gene
expression and each morphologic descriptor. Given a smaller
sample size of patients with expression and the knowledge
that higher levels of expression of wildtype APOL1 have also
been shown to be associated with kidney injury, we did not
adjust for or stratify by APOL1 risk alleles in this analysis.
The primary analysis was done only among patients with a
diagnosis of FSGS, given that this is the histology most
strongly associated with APOL1, and because of this, any
descriptors associated with APOL1 in a combined cohort of
MCD–FSGS may be driven more by the general FSGS de-
scriptors rather than those specific to FSGS. However, with
the rationale that APOL1 risk alleles may lead to specific mor-
phologic changes outside of FSGS, we also studied the asso-
ciation of genotype and gene expression only among the
MCD patients. For any descriptors showing a significant cor-
relation with genotype or gene expression, we additionally
conducted stratified analyses by pediatric (age < 18) or adult
status at the time of biopsy.
The Benjamini–Hochberg procedure was used to control
false discovery rate (FDR), since it is robust even when tests
are dependent. Descriptors with FDR-corrected p value less
than or equal to 0.1 were considered significant.
Analyses were restricted to participants with the available
data elements. Statistical analyses were conducted using R




The 90 Black participants included in the current study had a
median age of 16.5 years and were predominantly male
(62.2%); the majority had FSGS (61.1% vs. 38.9% MCD)
(Table 1). A greater proportion of participants with two
APOL1 risk alleles were born prematurely (p = 0.024).
Glomerular disease diagnosis and eGFR at biopsy also
differed across APOL1 genotype (p < 0.001 for both): partic-
ipants with no risk alleles predominantly had MCD and the
highest median eGFR, whereas those with two risk alleles
predominantly had FSGS and the lowest median eGFR. A
greater proportion of participants with zero or one APOL1 risk
alleles had immunosuppression use prior to biopsy compared
with patients with two APOL1 risk alleles (p = 0.045). In this
sample, number of APOL1 risk alleles and glomerular APOL1
gene expression were also significantly positively correlated
(Fig. 1, Spearman’s rank coefficient r = 0.46, p = 0.02).
APOL1 genotype and morphology
Almost all clinical associations with APOL1 risk variants
demonstrate the association of disease with two risk alleles
only (a recessive model). However, a small number of clinical
studies and a number of studies using molecular intermediate
phenotypes have demonstrated harmful impact associated
with each addition of a risk allele (additive model). Given this,
we tested the risk variants’ association with morphologic de-
scriptors under each of these models in patients with FSGS.
More specifically, under the recessive model, we compared
correlations between 29 participants with a HR genotype and
26 with a LR genotype. Under an additive model, the com-
parison was between 9, 17, and 29 participants with 0, 1, and 2
risk alleles, respectively.
Among the 54 patients with FSGS, one individual glomer-
ular descriptor one individual tubulointerstitial descriptor, and
one EM descriptor were significantly associated with APOL1
risk genotypes under both a recessive and additive model (Fig.
2, Supplemental Tables 1a and 1b). APOL1 risk variants were
significantly correlated with (1) decreased global mesangial
hypercellularity—“greater than 3 mesangial cells per
mesangial lobule involving > 50% of the visible mesangial
regions in a glomerulus” (additive: r = −0.44, p = 0.095;
recessive: r = −0.43, p = 0.057), (2) decreased condensation
of the cytoskeleton—“electron-dense cytoskeleton is
reorganized and condensed at the glomerular basement mem-
brane (GBM) aspect of epithelial cell (podocyte) foot process-
es” (additive: r = −0.39, p = 0.095; recessive: r = −0.39, p =
0.1), and (3) increased microcysts—“presence of dilated tu-
bules (> twice the diameter of a normal proximal tubule) con-
taining eosinophilic amorphousmaterial and generally accom-
panied by scalloping of the cast profile. The epithelium lining
the microcyst is generally flattened and does not reveal brush
border” (additive: r = 0.38, p = 0.095; recessive: r = 0.43, p =
0.057) (Fig. 3). There were no descriptors solely associated
with APOL1 in an additive or recessive model.
We then tested whether the significant associations of these
descriptors and APOL1 genotype discovered in FSGS patients
were replicated in the 36 patients with MCD. There were no
significant correlations observed. We recognized that the
smaller sample size could impact significance, so we also
Table 1 Characteristics of cohort under investigation
By Number of APOL1 risk alleles
Overall 0 risk alleles 1 risk allele 2 risk alleles p
N 90 28 28 34
Age at biopsy 16.5 (12.0–42.8) 13.5 (11.0–29.0) 16.5 (11.2–53.0) 17.5 (15.2–40.5) 0.276
Pediatric 54.4% (49) 60.7% (17) 53.6% (15) 50.0% (17) 0.697
Male 62.2% (56) 60.7% (17) 60.7% (17) 64.7% (22) 0.931
Hispanic 9.2% (8) 14.3% (4) 7.1% (2) 6.5% (2) 0.647
Premature 15.7% (13) 3.8% (1) 11.1% (3) 30.0% (9) 0.024
Histologic diagnosis < 0.001
MCD 38.9% (35) 67.9% (19) 39.3% (11) 14.7% (5)
FSGS 61.1% (55) 32.1% (9) 60.7% (17) 85.3% (29)
Immunosuppressant use before biopsy 26.7% (24) 35.7% (10) 35.7% (10) 11.8% (4) 0.045
RAASi use before biopsy 44.4% (40) 53.6% (15) 39.3% (11) 41.2% (14) 0.498
eGFR 81.3 (45.5–106.8) 103.6 (87.1–115.0) 79.5 (41.0–98.7) 54.1 (31.8–73.6) < 0.001
UPCR 2.5 (1.1–5.8) 2.0 (0.7–6.7) 2.0 (1.1–4.5) 3.6 (1.8–6.4) 0.289
# glomeruli in biopsy 29.0 (17.0–44.8) 31.0 (23.0–49.0) 33.0 (16.2–45.5) 21.0 (17.0–34.5) 0.125
All values are median (IQR) or % (N)
p values from Kruskal–Wallis rank sum test for continuous variables, Pearson’s chi-squared test for categorical variables with at least 5 participants in
each group, and Fisher’s exact test for categorical variables with less than 5 participants in at least one group, compared across number of risk alleles.
Variables with missing data and the number of participants with missing data in each group (0,1,2 risk alleles): Hispanic (0,0,3), Premature (2,1,4), eGFR
(0,2,6), UPCR (0,2,3), # Glomeruli (5,4,3)
examined the correlation point estimates. Under the additive
model, we observed, at a substantially decreased magnitude,
the same direction of effect for global mesangial
hypercellularity (r = −0.17) and condensation of the cytoskel-
eton (r = −0.20) in MCD patients. When using the MCD
participants as a “discovery cohort”, we did not observe any
significant correlations between APOL1 risk alleles and mor-
phologic descriptors.
Finally, we explored the associations of these descriptors
and APOL1 genotype in pediatric and adult patients separate-
ly. Although limited sample sizes could impact both signifi-
cance and the precision of the correlation point estimates, we
found that the correlat ions for global mesangial
hypercellularity were slightly stronger in pediatric patients
than adult patients and the correlations for microcysts and
condensation of cytoskeleton were stronger in the adult group
(Supplemental Table 2).
APOL1 gene expression and morphology
Glomerular APOL1mRNA expression data were available for
27/55 participants with FSGS, but no morphologic descriptors
were significantly correlated with glomerular APOL1 expres-
sion (Supplemental Table 3).
Discussion
Over the past decade, epidemiologic, translational, and basic
science research has led to innumerable insights about
APOL1-associated nephrotic syndrome. We have a greater
understanding of at-risk populations and the natural history
of individuals affected [4, 5, 14, 15], “second hits” that poten-
tiate APOL1’s penetrance [7, 23], and cell structures and path-
ways that are involved in the disease’s pathogenesis and pro-
gression [24–27]. At the same time, there are still many ques-
tions left on the table—answering them could ultimately con-
tribute to improved patient care.
The characteristics of the participants recruited and
samples collected in the NEPTUNE study provided us
with a patient population and set of data with which to
ask some fundamental questions about the relationship
between APOL1 genotype, glomerular expression, and
kidney tissue damage in unique ways: (1) the median
age of the cohort at the time of biopsy was 16 years old
(54% pediatric onset overall) which gave us a chance to
study the morphologic consequences of APOL1 in a co-
hort younger than previously reported; (2) we restricted
our cohort to only those of self-reported Black race or
African genetic ancestry, which allowed us to make com-
parisons between risk genotypes and expression among
these patients only. This prevented confounding by over-
all differences in genetic ancestry or by societal differ-
ences between races (e.g., structural racism against
Black individuals) [28]; (3) the spectrum of patients with
different number of risk alleles and available expression
data gave us the opportunity to study whether single cop-
ies of risk variants and/or increased glomerular expression
of APOL1 was associated with kidney damage, as report-
ed in other studies [9, 29–31]; (4) This is a case–case
study, which allows us to ask questions about how
APOL1 may be causing a unique form of nephrotic syn-
drome, rather than a case–control study comparing
APOL1-associated NS tissue to normal tissue; (5) the
availability of 83 validated histologic and ultrastructural
descriptors from light and electron microscopy created
and measured as part of the NEPTUNE protocol allowed
a level of morphologic granularity beyond that typically
reported in clinical biopsy reports.
Our primary analysis focused on studying the relationship
between APOL1 genotype and morphology under a recessive
model of inheritance in the subgroup of patients with FSGS.
The rationale for this choice was that (1) with rare exception,
published clinical studies of APOL1’s association with ne-
phrotic syndrome have observed harm for those carrying
two, but not one, risk alleles, and (2) APOL1 risk alleles are
enriched in FSGS compared to MCD, so there is risk of spu-
rious attribution of morphologic changes to APOL1 genotype,
rather than FSGS in general, if studying both groups of pa-
tients together.
The results of this analysis demonstrate significant correla-
tions between an APOL1 HR genotype with increased tubular
microcysts and both a decrease in global mesangial
hypercellularity and condensation of the actin cytoskeleton.
Fig 1 Glomerular APOL1 expression as measured by log2 transformed
mRNA level increases with increasing number of APOL1 risk alleles
In prior studies of CKD patients with arterionephrosclerosis
(and not NS), HIVAN, and collapsing glomerulonephritis
with lupus, HR APOL1 genotype was also associated with
increased prevalence of microcystic tubular dilatation [18].
The authors appropriately suggested that this indicates signif-
icant tubular injury in any APOL1-related kidney disease, and
here we extend this to FSGS as well.
Global mesangial hypercellularity, alternatively referred to
as diffuse mesangial proliferation, has been alternatively con-
sidered a histologic subtype of NS (“mesangioproliferative
NS”) [32, 33] or as a feature observed among patients with
MCD, FSGS, or other entities such as IgM or C1Q nephrop-
athy [34, 35]. Reports of the clinical implications of global
mesangial hypercellularity in patients with an NS picture vary
from being associated with higher chance of remission to be-
ing associated with worse outcomes when observed in a pa-
tient with FSGS. We interpret the lower frequency of global
mesangial hypercellularity observed among HR APOL1 pa-
tients to be indicative of the different mechanisms underlying
this form of FSGS. Future work incorporating our knowledge
Fig 2 Morphologic descriptors
associated with the APOL1 high-
risk genotype a presence of
tubular microcysts (yes/no), b
semiquantitative amount of
condensation of the actin
cytoskeleton, c percent of global
mesangial hypercellularity
of the pathobiology of mesangial hypercellularity may help us
understand how or why these pathways are less prominent in
APOL1-associated FSGS.
Among patients with FSGS, a HR APOL1 genotype is
also associated with less condensation of the actin cyto-
skeleton at the GBM aspect of the podocyte. Widespread
cytoskeletal condensation seen with diffuse podocyte ef-
facement is a classic feature of MCD [36]. But in a com-
parative ultrastructural study of adults with FSGS and
MCD, a significantly increased level of “mat-like conden-
sation of microfilaments” was observed among those with
FSGS [37]. The reasons for less condensation in the HR
state are not clear; explaining this phenomenon may en-
hance our understanding of its pathogenesis.
These three traits discovered using a recessive model were
also significantly correlated with APOL1 genotype under an
additive model. The harm associated with one risk allele in
this human study mirrors other reports that have found a del-
eterious impact of one risk allele, such as increased risk of
HIVAN [29] and cellular damage in model systems [30, 31].
It provides further support of the relevance to humans of the
potential harm coming from a single risk allele and, as
reviewed elsewhere, prompts us to further understand mech-
anistically why this may occur [38].
While clinical studies have not reported association of
APOL1 risk alleles with MCD, we hypothesized that they
would be associated with morphologic changes even in
MCD and that we would detect them in this study.
However, we detected no statistically significant associations
at all under the recessive or additive model in the MCD
subcohort. Our small sample size of MCD patients certainly
resulted in less power to detect significant associations, and it
may be that future studies with larger sample size will detect a
signature of APOL1 in kidneys affected by MCD.
Our availability of paired APOL1 genotype and glomerular
mRNA expression also allowed us to gain a number of in-
sights. In contrast to our 2015 paper (which studied APOL1
in NEPTUNE using microarray-based expression), here we
found that each additional APOL1 risk allele was associated
with its increased glomerular expression. We attribute this to
our current use of RNA-seq vs. previous use of microarray for
measurement of expression (with its higher dynamic range of
detection) and our study solely of FSGS patients rather than
patients of diverse histologies prior. Second, we did not ob-
serve any significant association between increased glomeru-
lar APOL1 expression and any morphologic changes. One
explanation for this is that we were only powered to discover
moderate to large changes and that the available sample size
did not empower us to discover small but significant associa-
tions. Another explanation is that because our sample size did
not allow us to study HR and LR APOL1 expression’s asso-
ciations with morphologic outcomes separately, we were un-
able to detect associations that were specific to a particular
genotype. Future studies of Black FSGS patients with in-
creased sample sizes should be able to address both of these
current limitations.
Fig 3 Representative examples of a tubular microcysts, b condensation
of the actin cytoskeleton, and c global mesangial hypercellularity from the
NEPTUNE cohort. a Tubular microcysts: the tubules are enlarged and
have an irregular shape. They contain eosinophilic smooth proteinaceous
material forming intratubular casts with scalloping of the edges of the
casts. (hematoxylin and eosin stain); b condensation of the
cytoskeleton: the cytoskeleton in podocytes with complete effacement
is reorganized and condensed against the abluminal side of the
podocytes facing the glomerular basement membranes (white arrow); c
global mesangial cell hyperplasia: these 2 glomeruli reveal increased
number of nuclei in the mesangium that is present in all glomerular
lobules. The number of mesangial cell nuclei is 4 or more in each
lobule. (Periodic acid Schiff stain)
While our study sample size was relatively large compared
with previous studies, it may have still been too small to detect
some statistically significant effects, especially after control-
ling for false discovery rate. The sample size also limited our
power and ability to adjust for all variables of interest or per-
form stratified analyses, particularly, the association of
genotype-dependent gene expression with morphology and
morphology by APOL1 within the MCD subcohort. We were
also unable to adjust or stratify by prior immunosuppressant
treatment, despite the finding that a greater proportion of pa-
tients with APOL1 LR genotype had immunosuppressant use
prior to biopsy compared with patients with APOL1 HR ge-
notype. However, if immunosuppressant use reversed tissue
damage prior to biopsy, we would expect to see fewer mor-
phologic changes in the LR group, contradicting the greater
changes we observed for condensation of cytoskeleton and
global mesangial hypercellularity. Finally, we did not detect
an association between these significant descriptors and any
other differentially expressed genes or coexpressed genemod-
ules. Future human-based studies, perhaps using single cell
RNA-seq, larger sample sizes, and/or proteomics, may possi-
bly be able to shed further light on these associations in a way
that we could not here. Despite this limitation, the availability
of APOL1 genotype, glomerular APOL1 gene expression, and
many detailed morphologic descriptors in many glomerular
disease patients is unique and a strength of our study.
By identifying associations between APOL1 genotype, glo-
merular APOL1 gene expression, and morphologic descrip-
tors, we uncovered some known and several novel associa-
tions in an FSGS-only subcohort. Taking these observations
to other human-based studies that are larger and/or have other
complementary molecular datasets while in parallel pursuing
them in cell lines and model systems may ultimately allow us
to better understand the pathobiology underlying nephrotoxic
effects of the APOL1 HR genotype.
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